A 3-month time-restricted eating (TRE) protocol resulted in up to one year of sustained weight loss in people with overweight ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

The new experimental weight loss drug, Retatrutide, is showing promising results. According to a study in the Annals of ...

have demonstrated significant weight loss of 14% over 68 weeks, tirzepatide 18% over 72 weeks, and retatrutide even 22% within 48 weeks. “These are numbers we cannot achieve with nutritional ...

Eli Lilly said on February 6 it plans to release data from its late stage drug trial on its experimental weight-loss drug retatrutide in 2025, a few months earlier than expected. The company had ...

which showed weight loss of around 19% at 46 weeks in a study reported earlier at the ADA, but had also not reached a plateau. Lilly is losing no time in advancing retatrutide into phase 3 testing ...

TUCSON, AZ / ACCESS Newswire / April 29, 2025 / Retatrutide, also known as LY3437943 ... contributing to weight loss and metabolic health improvements. This multi-receptor activation yields ...

Lilly’s retatrutide, a “triple agonist” shot, could match bariatric surgery’s 25% weight loss, potentially adding billions in revenue by 2026. Valuation supports the potential for LLY ...